Ranibizumab biosimilar(Senju Pharmaceutical Co., Ltd.)

This information material is provided for understanding Gene Techno Science (“GTS”), not for soliciting investment in GTS shares. Information provided in this material may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include success rate of R&D projects, new regulations and rules, relations with partners in the future, etc. This material includes information on pharmaceutical products and regenerative medicine (or related products), etc., which is being developed or launched. However, this is not intended to promote our products or provide medical advices. Application for manufacturing and marketing approval of GBS-007. Joint Research with Hokkaido University and Spinal Injuries Center for Non-Union Fractures. Acceleration toward application for manufacturing and marketing approval of JRM-001 (by mid FY 2023).